Home > Journals > Minerva Pediatrics > Past Issues > Minerva Pediatrica 2019 December;71(6) > Minerva Pediatrica 2019 December;71(6):524-32

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Pediatrica 2019 December;71(6):524-32

DOI: 10.23736/S0026-4946.19.05513-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Measurement of nitric oxide and assessment of airway diseases in children: an update

Maria G. PAPPALARDO 1, Giuseppe F. PARISI 1 , Lucia TARDINO 1, Salvatore SAVASTA 2, Ilaria BRAMBILLA 2, Gian L. MARSEGLIA 2, Amelia LICARI 2, Salvatore LEONARDI 1

1 Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 2 Department of Pediatrics, San Matteo Polyclinic, IRCCS and Foundation, University of Pavia, Pavia, Italy



INTRODUCTION: Nitric oxide (NO) is a gas synthesized by the inducible NO synthase enzyme in airway cells and it is thought to make important functions in the airway inflammation of several respiratory diseases.
EVIDENCE ACQUISITION: This current study is a review of the literature from 1990 to present about NO and its use in clinical practice. The databases used were PubMed, Scopus, and Cochrane Library.
EVIDENCE SYNTHESIS: At the respiratory level there are three different measurements sites of NO: nNO (nasal nitric oxide), FeNO (exhaled fraction of nitric oxide), CaNO (alveolar nitric oxide). Each of them is produced at different levels of the respiratory tract and is involved in various diseases. nNO finds its use, principally, in the allergic rhinitis in fact it can be used as a measure of therapeutic efficacy, but not for the evaluation of the severity; also in primary ciliary dyskinesia (PCD), where high levels exclude the disease, and in chronic rhinosinusitis, but it is not currently used as a diagnostic or prognostic marker. FeNO has a greatest use in bronchial asthma, particularly, it is considered a non-invasive biomarker to identify and to monitor airway inflammation but currently, there is not a consensus on the use of the FeNO in the management of asthma treatment. Finally, CaNO is the least used in clinical practice, because lack of standardization of measurement techniques.
CONCLUSIONS: Nitric oxide is a sensitive indicator of the presence of airway inflammation and ciliary dysfunction, although some studies have shown varying or conflicting results.


KEY WORDS: Nitric oxide; Respiratory tract diseases; Child

top of page